Protalix BioTherapeutics (PLX) Finished Goods (2012 - 2026)

Protalix BioTherapeutics' Finished Goods history runs 10 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• In Q1 2026, Finished Goods rose 119.15% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (up 119.15% YoY), while the FY2025 annual figure was $10.4 million, up 90.38% from the prior year.
• Finished Goods was $15.4 million for Q1 2026 at Protalix BioTherapeutics, up from $10.4 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $15.4 million in Q1 2026 to a low of $706000.0 in Q3 2024.
• Historically, Finished Goods has averaged $9.0 million across 5 years, with a median of $9.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Finished Goods plunged 91.46% in 2024, then soared 1446.32% in 2025.
• A 5-year view of Finished Goods shows it stood at $10.6 million in 2022, then tumbled by 45.24% to $5.8 million in 2023, then slipped by 6.28% to $5.4 million in 2024, then soared by 90.38% to $10.4 million in 2025, then soared by 48.29% to $15.4 million in 2026.
• The last three Finished Goods figures came in at $15.4 million (Q1 2026), $10.4 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.